NATURE OF STUNNING OF THYROID TISSUE

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。令人震惊是由先前诊断性131-I给予的辐射引起的治疗性131-I动力学的改变，据说发生在分化良好的甲状腺癌患者的残留甲状腺组织中。本研究项目将验证以下假设：在甲状腺癌患者中，低量131-I（诊断）后残留甲状腺组织中131-I的丢失模式与大量131-I（治疗）后的丢失模式不同。将招募10名在甲状腺切除术后接受131-I治疗残留甲状腺组织的患者。将对组织的连续核医学图像进行量化，以确定诊断性131-I和后续治疗性131-I的消失模式，每个持续7天。引入了一种更容易被潜在受试者接受的替代方案：仅在2天内获得诊断性131-I的图像并进行定量;这一有限的时间足以在初始摄取时比较诊断性和治疗性131-I。 这些图案应该可以提供击昏的证据，或者提供更大的治疗用131-I的辐射效应的证据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Stunning, an alteration in the kinetics of therapeutic 131-I induced by the radiation imparted from a prior diagnostic 131-I, is said to occur in residual thyroid tissues of patients with well-differentiated thyroid cancer. This research project will test the hypothesis that, in patients with thyroid cancer, the pattern of loss of 131-I from residual thyroid tissues after low amounts of 131-I (diagnostic) will differ from the pattern of loss after large amounts of 131-I (therapeutic). Ten patients who are to be treated with 131-I for their residual thyroid tissues after surgical thyroidectomies will be recruited. Serial nuclear medicine images of the tissues will be quantified to determine patterns of disappearance of diagnostic 131-I and of subsequent therapeutic 131-I, each over 7 days. An alternative protocol that was more acceptable to potential subjects was introduced: Images of the diagnostic 131-I will be obtained and quantified for only 2 days; this limited period is sufficient for comparing diagnostic and therapeutic 131-I at the time of initial uptake. The patterns should provide evidence either for stunning or, alternatively, for a radiation effect from the larger therapeutic 131-I.